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Abstract The influence of the microenvironment through
the various steps of cancer progression is signed by
different cytokines and growth factors, that could directly
affect cell proliferation and survival, either in cancer and
stromal cells. In colon cancer progression, the cooperation
between hypoxia, IL-6 and VEGF-A165 could regulate the
DNA repair capacity of the cell, whose impairment is the
first step of colon cancer development. This cooperation
redirects the activity of proteins involved in the metabolic
shift and cell death, affecting the cell fate. The pathways
triggered by micro environmental factors could modulate
cancer-related gene transcription, affecting also small non
coding mRNA, microRNAs. MicroRNAs have emerged as
key post-transcriptional regulators of gene expression,
directly involved in human cancers. The present review
will focus first on the intertwined connection between
cancer microenvironment and aberrant expression of
microRNAs which contribute to carcinogenesis. In partic-
ular, the epigenetic mechanisms triggered by tissue micro-
environment will be discussed, in view of the recent
identification of miRNAs able to directly or indirectly
modulate the epigenetic machinery (epi-miRNAs) and that
are involved in the epithelial to mesenchimal transition and
metastases development.
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Abbreviations
CPT1 Carnitine palmitoyl transferase 1
CRC Colorectal cancer
DNA DSBs DNA double strand breaks
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
EMT Epithelial-mesenchymal transition
FASN Fatty acids synthase
HDAC Histone deacetylase
HIF-1 Hypoxia inducible factor-1
HR Homologous recombination
IL-1 Interleukin-1
IL-6 Interleukin-6
miRNAs Micro RNAs
NHEJ Non homologous end joining
s-CLU Secreted clusterin
sIL-6R IL-6 soluble receptor
TAMs Tumor associated macrophages
TGF-β Transforming growth factor-beta
TIMP-1 Tissue inhibitor of metalloproteinase 1
VEGF Vascular endothelia growth factor
Introduction
Colon cancer develops as a result of the pathologic
transformation of normal colonic epithelium to adenoma-
tous polyp, which ultimately leads to invasive cancer [1–3].
Tumor induction and progression are characterized by
accumulation of multiple genetic and epigenetic alterations,
that confer a selective reproductive advantage to a clone,
within a genetically unstable heterogeneous cell population
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DOI 10.1007/s12307-011-0062-y[2, 4, 5]. The survival and the expansion of the neoplastic
cell clone are supported by the surrounding tissue that
sustains and favours these conditions [6, 7]. Tumor-
associated stroma actively fuels the colon cancer progres-
sion [6]. Among the tumor-associated cells are endothelial
cells and pericytes that form the neo-vasculature. In turn,
the newly formed angiogenic blood vessels supply tumor
cells with nutrients and oxygen. In addition, mesenchymal
cells are present in the stroma at earlier tumor stages,
suggesting a co-evolution between stromal and cancer cells
that leads to clonal expansion and metastasis [7]. Chronic
inflammation, such as inflammatory bowel disease may
predispose to malignancy and tumor progression. The
chronic inflammatory microenvironment consists of
immune, inflammatory and stromal cells, all of which
produce cytokines, growth factors and adhesion molecules
that may sustain tumor growth, its progression and
spreading [8, 9].
The cytokines and growth factors produced by cancer
cells function to create optimal growth conditions within
the tumor microenvironment, while cytokines secreted by
stromal cells may influence the behaviour of malignant
cells. Pro-inflammatory cytokines (IL-6, IL-1) [10–12],
growth factors (such as VEGF, TGF-β-1, -2, -3) and their
cognate receptors [13–16] either in cancer and in stromal
cells, influence not only primary gene transcription, but
activate several pathways that cooperate to the aberrant
clone survival, tumor expansion and metastasis [6, 10, 12].
In addition, alteration of microenvironmental factors
induced by hypoxia, represents an hallmark of cancer
progression [17, 18].
In this review, we discuss the role played by miRNA in
colon cancer initiation and progression, especially in the
context of the synergism existing among hypoxic condition,
expression of IL-6 pro-inflammatory cytokine and
up-regulation of VEGFA165 [19]. We report that this
cooperation could act on the neoplastic cell, also by the
dysregulation of miRNAs involved in colon cancer pro-
gression relevant pathways. Both the over-expression and
the silencing of specific miRNAs are associated with the
development and progression of colorectal cancer [20].
Recent studies have identified specific miRNAs present
in colorectal cancer tissues and blood that may aid the
diagnosis of cancer and help to predict disease recurrence
[20–22]. Such a role in oncogenesis suggested that
miRNAs could represent important targets for gene thera-
pies. Although little is known about the exogenous factors
that interfere with the regulation of miRNA expression, the
microenvironment seems to play an essential role, affecting
the epigenetic mechanisms that modulate miRNA gene
expression, including methylation, histone deacetylation, or
influencing the function of proteins involved in the
maturation processing of microRNAs [23, 24]. The present
review will focus on the peculiar relationship between
colon cancer cells and microenvironment, that could
influence miRNAs dysregulation, the apoptosis escaping
and the metabolic shift, leading to invasion and metastasis.
miRNA Dysregulation and Histone Hypo-acetylation:
A “Must” of the Metastatic Cell
MicroRNAs (miRNAs) are ~22-nt small noncoding RNAs
that are processed from larger (80-nt) precursor hairpins by
the RNase III enzyme Dicer into miRNA:miRNA duplexes.
One strandofthese duplexesassociateswiththe RNAinduced
silencing complex (RISC), whereas the other is generally
degraded. The miRNA–RISC complex targets messenger
RNAs triggering either translational repression or mRNA
degradation [25]. The total number of miRNAs that are
encoded in the human genome remains to be clarified.
Initial estimates suggested there were up to 255 human
miRNAs, but cloning and bioinformatic analyses have
demonstrated that there are numerous nonconserved
human miRNAs and suggest this number may be
significantly larger [26]. Thousands of mammalian mes-
senger RNAs are under selective pressure to maintain
nucleotide sites matching microRNAs. Usually conserved
targets are often highly expressed at developmental stages,
before miRNAs expression and their levels tend to fall as
the miRNA that targets them begins to accumulate. The
phenomenon of the selective avoidance extended to
thousand of genes enables temporal and tissue specific
miRNA expression pattern, playing an important role in
developmental timing [27]. It seems that the acquired
differentiation and specialization is profoundly influenced
by the impact of microRNA on mRNA repression and
evolution. Overall, in a well differentiated tissue miRNAs
are destabilizing many target messages to define tissue-
specific transcript profile, but other targets could be
modulated at translational level, without mRNA degrada-
tion. In that regard, changes of microenvironmental factors
(as seen during cancer development) could accurately
modulate protein expression patterns, acting on miRNA
expression. A primary consequence in the transition from
differentiated normal to de-differentiated neoplastic cell is
the down modulation of miRNAs, involved in tissue
specific differentiation. In humans, aberrant expression of
miRNAs contributes to carcinogenesis by promoting the
expression of proto-oncogenes or by inhibiting the
expression of tumor suppressor genes. Such oncomirs
have been demonstrated in a variety of haematological and
solid tumors [28] and they contribute to cancer develop-
ment and progression [20–22]. Recently, the altered
miRNAs expression in colon cancer has been reported
(Table 1). However, the role that miRNAs play in the
development of metastasis is more poorly defined [29]. It
156 S. Pucci, P. Mazzarelliis worth of note that the same miRNAs could exert tumor
suppressor or oncogenic effects, depending on the tumoral
context and the stage of neoplastic disease. Recently,
A r n d te ta l .[ 67] have shown that the re-expression of
miR-143 or miR-145 leads to tumor suppressor and
oncogenic phenotypes respectively, in a metastatic CRC
model. In particular miR-145, reported as a ‘tumor
suppressor’ in a non-metastatic context, showed oncogen-
ic effects associated with the down-regulation of the G1/S
cell cycle checkpoint and neuregulin pathways in the CRC
metastatic setting.
ThecancermicroenvironmentcouldcontributetomiRNAs
dysregulation affecting the epigenetic mechanisms (such as
DNA methylation or histone acetylation) that regulate
miRNA expression or influencing the maturation process of
microRNAs [23, 24, 30].
Cancer Microenvironment and Development of Metastases:
The Role of VEGF-A165a and IL-6
As previously reported [31], DNA repair failure and cell
survival represent the first step in colon cancer expansion.
The pro-inflammatory cytokine IL-6 seems to play a role in
the inactivation of DNA repair mechanisms and Bax-
dependent apoptosis. Although data on the relationship
between IL-6 production and tumor progression are still
conflicting, recent studies suggest a pathogenetic function
of the complexes formed between IL-6 and its soluble
receptor (sIL-6R), in colon carcinoma. It seems that an
increased formation of IL-6-sIL-6R complexes, able to
interact with gp130 on the cell membrane (trans-signaling),
leads to an increased expression and nuclear translocation
of STAT3, which can cause the induction of anti-apoptotic
genes, such as the Bax antagonist Bcl-xL protein [10, 32,
33]. Moreover, it has been observed that in critical
conditions (hypoxia, glucose deprivation, oxidative stress),
the activation of STAT3, together with increased levels of
HIF1α (triggered by the hypoxic condition, 1% pO2)
influences the preferential expression of VEGF-A165a
isoform [17, 18, 33], that could lead to the inhibition of
programmed cell death inducing anti-apoptotic Bcl-2
protein. Two different splicing isoforms of VEGF165 have
been identified, exerting pro- or antiangiogenic actions
respectively and whose formation is strictly controlled by
micro-environmental factors [34]. The production of pro- or
anti angiogenic forms of VEGF depends upon splice site
choice in the C-terminal. Proxymal splice site selection in
exon 8 generates pro-angiogenic isoforms such as VEGF-
A165a, and distal splice site selection results in the
antagonistic anti-angiogenic isoforms the VEGF-A165b.
Cellular choice on splice site selection, strongly influenced
by microenviromental factors, depends upon the activity of
RNA-binding splice factors, such as ASF/SF2. Recent
studies showed a nuclear and cytoplasmic localization of
ASF/SF2 splicing factor and correlated the cytoplasmic
localization to the inhibition of the proangiogenic form and
to a strong increase of the anti-angiogenic isoform b
[34, 35].
In colon cancer, it seems reasonable that the cooperative
interaction between IL-6 and increased levels of HIF1α
favours the shift versus the VEGF-A165 pro-angiogenic
isoforms, all these factors contributing ultimately to tumor
cell proliferation, apoptotic escaping and cell migration.
Along these lines, we found an increase of IL-6 protein
levels in human colon cancer tissues and the increase was
positively correlated with the tumor stage [36]. IL-6,
released as by the tumor itself as by tumor associated
macrophages (TAMs), together with IL-6-induced VEGF-
A, could influence tumor cell survival interfering with the
Ku-CLU-Bax physical interactions. In a colon cancer
progression model, we had previously demonstrated that
IL-6 increased the expression of s-Clusterin (sCLU), a
multifaceted protein strongly involved in cell survival,
apoptosis escaping and metastasis [36–39]. In vitro experi-
ments have showed that the Ku-CLU-Bax interactions are
modulated by IL-6, and IL-6 together with VEGF-A165
inhibit Bax-dependent cell death increasing the production
of the clusterin pro-survival form (sCLU), finally shifting
death into survival. In a moderately differentiated colon
cancer cell line IL-6 down-modulated Bax expression at
mRNA level. Concomitantly, IL-6 exposure influenced Bax
at protein level acting on Bax-Ku70-sCLU physical
interactions in the cytoplasm. In particular, it affected the
acetylation and phosphorylation state of Ku70 [36]. The in
vitro treatment with IL-6 and VEGF-A165 modulated the
expression of genes involved in tumor invasion and
apoptosis, as observed by microarray analysis [36]. In
Table 1 miRNAs dys-regulated in colorectal cancer
Human miRNAs References
Down-regulated Let-7 family [59]
miR-29 [66, 68]
miR-34a [60]
miR-143 [61]
miR-145 [67]
miR-663 (targeting TGF-β1) [64]
miR-31 [65]
Up-regulated miR-106b-93-25 [69]
miR-155 [70]
miR-21 (epigenetic switch) [62, 63, 66]
miR-181b-1 (epigenetic switch) [62]
Hypermethylated miR-124 [71, 72]
miR-34b [60, 71, 72]
miR-137 (epigenetic silencing) [24]
MicroRNA Dysregulation in Colon Cancer 157particular, microarray data showed that IL-6 could influ-
ence cell proliferation, not only by inducing AP1 formation,
but also through the up regulation of RASp21 protein
activator 1, myc and NFκB. On the other hand, IL-6 down-
modulated the expression of genes involved in the inhibition
ofmetastasis,suchasTIMP1metallopeptidaseinhibitor1and
KISS1 [40, 41]. These still unclear molecular interactions,
underline the relevant role of the microenvironmental factors
in the complicated cross talk among molecules that could
effectively turn the cell fate, by a fine regulation of gene
expression, also acting on miRNA expression.
VEGF-A165a and IL-6: A Microenvironment Cooperation
Leading to Metastasis Through MicroRNA Dysregulation
Changes of the microenvironment mediators induced by
hypoxia, represent an hallmark of cancer progression. In the
tumoral context, the transcriptional regulator hypoxia-
inducible factor (HIF1α), cooperates with IL-6, TGF-β
and VEGF-A165 in the promotion of tumoral growth
[10, 15, 17–19].
The activation of hypoxia fosters neo-angiogenesis also
regulating the expression of miR-210, and its target Ephrin-
A3, involved in tube formation and survival of endothelial
cells [42]. A group of candidate miRNAs regulated by
hypoxia have been recently identified: miR-16, 20let-7b,
miR-17-5p, miR-27, miR-106, miR-107 miR-193, miR-
210, miR-320 and miR-361, showing VEGF as potential
target [43, 73]. Moreover, using a bioinformatic prediction
program, several key genes of proliferation, metabolism,
migration and apoptotic response (miR-23, miR-26, miR-
27, miR-30, miR-181) were found to be potentially targets
of hypoxia-regulated miRNAs [57, 58]. In the colon cancer
context, the synergism among hypoxic condition (HIF-1α
activation) and IL-6 pro-inflammatory cytokine induces the
up-regulation of VEGF-A165, contributing to neoangio-
genesis and metastasis formation.
In colon cancer cells (Caco-2), we observed that the
synergismofIL-6andVEGF-A165 influencedthe expression
of tumor suppressor miRNAs, involved in epigenetic control
and epithelial to mesenchymal transition (EMT), which
strongly correlated to the malignization of many types of
cancers [6]. In particular, the in vitro co-treatment with IL-6
and VEGF-A165 significantly down modulated miR-619,
which targets VEGF gene expression determining a positive
feed-back loop, finally contributing to cancer growth and
spreading [44]. In addition, a significant decrease of miR-
200 (12-folds decrease) was found, as compared to untreated
colon cancer cells. The target prediction program indicates
that highly conserved binding sites for the miRNA200
family are present in the ZEB1 and SIP1 mRNAs, which
are repressors of ecadherin, implicated in EMT transition and
tumor metastasis. The same down-regulation of miR-200
was obtained in response to TGF-β treatment and this effect
was sufficient to induce EMT, in a process requiring up-
regulation of ZEB1 and/or SIP1 [45]. In addition, Adam et
al. [46] demonstrated that miR-200 controls the sensitivity to
the EGFR therapy, which represents an actual issue in the
treatment of human highly aggressive and metastatic
colorectal cancer. In fact the expression of the miR-200 is
sufficient to restore the EGFR dependency in bladder cancer
cells, targeting ERRFI-1 which is a novel regulator of
EGFR-independent growth.
In the last years, great attention has been given to the
development of target anti-cancer therapies, based on the
knowledge of transcriptional mechanisms epigenetically
regulated in tumoral tissues. Moreover, it has been
recently delineated a reciprocal interconnection between
microRNAs and epigenetics [30]. The epigenetic mod-
ifications, such as DNA methylation or histone acetyla-
tion, are able to affect miRNAs expression causing
oncomirs dysregulation, but the same microRNA (epi-
miRNAs) may directly control the epigenetic machinery
targeting its enzymatic components [30].
Evidence of the epigenetic influence of the microenvi-
ronment on tumoral cells has been observed by co-treating
colon cancer cells with IL-6 and VEGF-A165. A strong
down-modulation of the growth suppressing miR-449,
which targets histone deacetylase 1 molecule (HDAC-1)
[47] has been found in our system. This enzyme plays a
crucial role in the epigenetic control and display high
significance in oncology [48, 49]. Aberrant HDAC level
and/or sustained activity has been found in various types of
cancer and metastasis [50]. It has known that recruitment
and activation of HDACs results in tightening of chromatin
structure, thus the transcriptional machinery is prevented
from accessing the DNA. Hence, cytokines and growth
factors in the microenvironment could modulate gene
transcription at epigenetic level, affecting epi-miRNA (as
miR-449 [47]), or influencing the activity of protein
involved in the regulation of HDAC activity (Fig. 1).
miRNAs Expression and Altered Metabolism in Cancer
The altered metabolism of tumor cells may be a potential
means by which these cells evade programmed cell death,
favoring survival and tumoral growth. In particular, the
metabolism of fatty acids is markedly altered in the tumoral
context. It has been demonstrated that the extracellular
acidosis in the microenvironment of solid tumors can work
in an epigenetic fashion by up-regulating the transcriptional
expression of fatty acids synthase (FASN) gene, proposed
as the “metabolic oncogene” of cancer cells [51].
Recent reports demonstrated the existence of miRNAs
able to recognize and modulate the transcriptional levels of
metabolic factors, relevant both in non neoplastic and in
158 S. Pucci, P. Mazzarellicancer cell. In particular, transfection experiments with
sense and antisense sequences displayed that the increase of
lipogenesis in HepG2 cells (hepatocarcinoma cell line) is
directly controlled by miR-122 [52]. This miRNA sequence
is up-regulated by miR-370, the last therefore indirectly
involved in the upregulation of lipogenic genes. Interest-
ingly the same miR-370 targets the 3′UTR of CPT1, down-
regulating the expression of CPT1A gene and the rate of
β-oxidation [52].
Carnitine palmitoyl transferase 1 (CPT1) is another
limiting factor in the fatty acids metabolism and it is
contra-regulated by FASN substrate malonyl-CoA [53].
CPT1 resides physiologically at the mitochondrial mem-
brane transporting long-chain fatty acids for β-oxidation.
Recently, a CPT1A transcript splice variant, termed
variant 2 (NM_001031847), was identified in colon cancer
and breast cancer cells and it was undetectable in the
corresponding non neoplastic cell line [53]. This variant
codifies for a protein which dif f e r si no n l y1 1a m i n o a c i d s
from CPT1A variant 1, at the C-terminus. The preferential
cellular localization of the two CPT1A variants was
identified, being the product of transcript variant 2 mainly
localized in the nucleus of tumoral cells.
The two transcript variants of CPT1A show great
similarity differing only at the 3′-UTR level, where the
recognition with miR-370 is located [52]. A different
effectiveness of miR-370 in the target recognition could
be responsible for the different levels of CPT1A transcripts
Fig. 1 Cancer- stroma interactions in colon cancer progression and
spreading. In colon cancer the synergistic action of IL-6, and VEGF-
A165a promotes the acquisition of aggressiveness regulating the DNA
repair capacity of the cell, whose impairment is the first step of colon
cancer development. The cooperative action of these soluble media-
tors could modulate cancer-related gene transcription (sClusterin,
TIMP1), and affect the expression of small non coding mRNA
(microRNAs), able to modulate the epigenetic machinery (epi-
miRNAs; miR-449) and to induce the epithelial to mesenchimal
transition (EMT induction; miR-200 family)
MicroRNA Dysregulation in Colon Cancer 159found in cancer cell, as compared with non neoplastic cell.
In fact, miR-370 could preferentially target CPT1 isoform 1
and indirectly favour CPT1 isoform 2, localized in the
nucleus of cancer cells.
Experiments performed on human colorectal and breast
tumoral tissues and cancer cell lines (Caco-2, HepG2 and
MCF-7 cells) showed that the nuclear localization of
CPT1A correlated to an increased HDAC activity and a
resulting decrease of histone acetylation [53]. Moreover,
HDAC-1 protein co-precipitated with CPT1A.
We have evidence of a different binding affinity of the
two CPT1A variants for HDAC1. These data are based
on the dissimilar CPT1 residues at the interface with
HDAC1, for the two complexes. In the case of isoform 2
the interaction with HDAC1 involved a region close to
the C-terminus, where the differences with CPT1 isoform
1 are located. Considering the great similarity of the
other regions of CPT1 isoforms, this evidence suggested
a higher stability of the complex CPT1 isoform2/HDAC1
(unpublished data). HDAC complexes are recruited to
specific genomic sites by regulatory proteins. Additional
data are needed to confirm if CPT1 (and in particular the
nuclear isoform) could function as a novel partner of
HDAC-1, stabilizing HDAC complexes at acetylated-
histone tails of specific promoters, to silence tumor
suppressor genes involved in the control of cancer cell
growth and migration.
Altered Metabolism and Cancer Microenvironment
Experimental evidence suggest that, in tumoral context, the
modulation of the metabolic factors could be driven by
miRNA target recognition [52], but also through the
activation of membrane receptors signalling, such as EGF/
EGFR family, induced by microenvironmental stimuli
[51, 54].
The human epidermal growth factor receptor type 1
(EGFR/HER-1) gene encodes a membrane receptor protein
in the epidermal growth factor receptor family (ERBBs)
and evidence suggests that EGFR expression and its
activation status are associated with hyper-proliferation of
colon cancer cells. Increased expression of EGFR is
independently associated with poor disease-free survival
after adjustment for stage, histological grade, age, and DNA
mismatch repair status [55]. Epidermal growth factor and
the EGF receptors (known as ERBB1) and ERBB2 have
been shown to stimulate fatty acids synthase (FASN), the
major enzyme required for the synthesis of fatty acids,
although the ultimate mechanisms responsible for tumour-
associated FASN overexpression are not completely under-
stood. The effects of growth factors and growth factors
receptors on FASN are complex and involve activation and/
or cross-talk between multiple signal-transduction pathways
[56] The EGFR activation found in colorectal cancer [55]
could induce an up-regulation of FASN, determining the
down-regulation of CPT1A activity in mitochondria [53].
Overall, in the neoplastic cells the gradient of micro-
environmental factors (including EGF/EGFR activation)
induces the overexpression of FASN and the resulting
inhibition of fatty acids β-oxidation. Thus, a differential
expression of CPT1A isoforms, driven by miRNA target
recognition [52], could favour the CPT1 nuclear variant that
evidence suggest to be implicated in the epigenetic
regulation [53].
In conclusion, the metabolic factors altered in cancer
could directly regulate the expression of genes implicated
in tumor development and metastases, or modulate at
epigenetic level the expression of small non coding
RNAs. Besides, microRNAs have been identified (and
many others remain to be uncovered) that target
metabolic factors modulating their expression. Once
more this regulatory loop se e m st ob ed r i v e nb ym i c r o -
environmental factors.
Conclusion and Perspectives
Invasion and metastasis are the deadly face of malignant
tumors. Considering the high rate of incidence and
mortality of colorectal cancer, it is critical to determine
the mechanisms of its dissemination. The outcome of this
non random process depends, in part, on the interaction of
unique tumor cells with a compatible organ microenviron-
ment. On the other hand, overexpression and silencing of
specific miRNAs are associated with the development and
progression of colorectal cancer. It is worth of note that
miRNA dysregulation could play opposite role in the early
stages of colon cancer, as compared to a metastatic context.
As reported above, the pathway analyses may explain the
observed oncogenic effects of miR-145 in metastatic CRC,
compared to its reported tumor suppressor effects in the
non-metastatic context [67].
The present review attempts to shed light on the fine
relationship between altered gene expression profiles
implicated in colon cancer progression and regulatory
miRNAs, induced by pro-inflammatory partners of tumor
microenvironment. Furthermore, in the neoplastic cells the
gradient of microenvironmental factors induces the alter-
ation of metabolic enzymes, such as FASN and CPT1A,
which act on the epigenome modulating miRNA expres-
sion. The other side of the coin is represented by the
identification of miRNAs which target the same metabolic
factors, modulating their expression levels. Nowadays, the
identification of specific miRNAs directly involved in
cancer spread and metastasis may signify novel diagnostic
tool in the characterization of gene targets.
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